| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 263.9 | 248.1 | 222.4 |
| Other income | 3.9 | 5.1 | 3.6 |
| Total income | 267.8 | 253.2 | 226.0 |
| Profit before exceptional items & tax | 23.3 | 22.9 | 23.6 |
| Profit before tax | 23.3 | 22.9 | 23.6 |
| Net profit | 18.1 | 17.7 | 17.8 |
| Operating margin | 8.7% | 9.0% | 10.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1.70% |
|---|---|
| Net profit, quarter on quarter | +2.30% |
| Revenue, year on year | +18.70% |
| Operating profit, year on year | -3.00% |
| Operating profit, quarter on quarter | +9.00% |
BSE results filing, NSE: WINDLAS. Figures extracted from the filing.
Windlas Biotech Ltd: key numbers
- Share price
- ₹921.25
- Market cap
- ₹1,934 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 29.1×Sector 37.9×
- Promoter holding
- 63.31%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Management Change
Windlass Biotech reports Mr. Ashok Kumar Windlass ceased as Executive Director, resigning for succession planning, effective 5 November 2026. He moves to Founder President, and Hitesh Windlass becomes Managing Director.
Windlas Biotech Results Update
Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.
Windlas Biotech Investor Presentation: Key Takeaways
H1FY27 revenue Rs 512 Cr (+18%), adj. PAT Rs 50 Cr (+33%, 9.7% margin); reported PAT flat at Rs 36 Cr on ESOP charges. CDMO-led growth; Plant-6 commercialised.
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Windlas Biotech Board Meeting Date
Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.
Windlas Biotech Other Announcement
This quarterly shareholding pattern statement for Windlas Biotech Ltd, covering the period ended September 30, 2026, provides the company's equity ownership breakdown.